ASC-J9: Phase IIa data

Data from a double-blind, U.S. Phase IIa trial in 186 patients showed that 0.025% topical ASC-J9 twice daily reduced inflammatory lesions at 12 weeks vs. vehicle. The study was not powered for signifi...